ArticleACR open rheumatology2026
An Engineered Glove for the Objective Assessment of Hand Dexterity in Patients With Systemic Sclerosis.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHand disability is a major musculoskeletal functional impairment in systemic sclerosis (SSc), but its objective assessment remains challenging. The validated Hand Test System (HTS) engineered glove has provided quantitative dexterity data in rheumatic diseases. The primary objective was to evaluate the applicability of the HTS glove in patients with SSc by comparing its parameters (touch duration [TD], intertapping interval [ITI], and movement rate [MR]) with healthy controls (HCs). The assumptions were that HTS parameters would be significantly impaired in patients with SSc and would correlate with clinical, imaging, and patient-reported outcome measures (PROMs).
methodsA cross-sectional study was conducted enrolling 25 patients with SSc (fulfilling 2013 American College of Rheumatology/EULAR criteria) and 25 matched HCs. The main outcome variables were the HTS glove parameters. All participants also underwent grip strength measurement and an assessment of PROMs (Scleroderma Health Assessment Questionnaire and Duruöz Hand Index), together with a performance-based evaluation of hand mobility using the Hand Mobility in Scleroderma test. Clinical and imaging data were collected for patients with SSc including the modified Rodnan skin score (mRSS) and high-frequency skin ultrasonography (HFSU) to measure hand and total body dermal thickness.
resultsPatients with SSc performed finger movements significantly more slowly and less efficiently than HCs, demonstrated by prolonged mean TD and ITI and reduced MR (P < 0.05 for all). In patients with SSc, HTS parameters significantly correlated with poorer PROMs (0.39 < r < 0.65, all P < 0.01 for all). Notably, both mean TD and ITI directly correlated with the mRSS (0.40 < r < 0.48, all P < 0.05). Furthermore, the mean TD showed a significant direct correlation with HFSU-measured dermal thickness of the dorsum of the hands and with total body dermal thickness (P < 0.05 for all). No significant differences in HTS parameters were detected based on nailfold videocapillaroscopy findings or organ involvement.
conclusionThe HTS glove provides objective measures of the impaired hand dexterity in SSc. The significant correlations between HTS parameters, PROMs, mRSS, and HFSU-measured dermal thickness suggest a significant relationship between skin fibrosis and functional hand disability. The HTS glove seems a promising tool for objectively monitoring SSc hand outcomes, and studies to explore its utility in monitoring therapeutic responses are in progression.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.